Efficacy and Safety of 177Lu-PNT2002 PSMA Therapy in Metastatic Castration-Resistant Prostate Cancer in the SPLASH - Neil Fleshner

Details

Charles Ryan is joined by Neil Fleshner to discuss the efficacy and safety of radioligand 177Lu-PNT2002 in PSMA-positive patients with metastatic castration-resistant prostate cancer (mCRPC) who progressed after treatment with androgen receptor axis-targeted therapy (ARAT) in the SPLASH trial. Drs. Ryan and Fleshner start by discussing the issue of dosimetry and why it was important for the FDA to...